BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15 | +66.7% | 550 | 0.0% | 0.00% | – |
| Q2 2023 | $9 | -93.5% | 550 | -93.4% | 0.00% | -100.0% |
| Q1 2023 | $138 | +165.4% | 8,297 | +22.5% | 0.00% | – |
| Q4 2022 | $52 | -99.9% | 6,775 | -23.1% | 0.00% | -100.0% |
| Q3 2022 | $88,000 | +1660.0% | 8,808 | +1501.5% | 0.00% | – |
| Q2 2022 | $5,000 | +25.0% | 550 | +28.2% | 0.00% | – |
| Q1 2022 | $4,000 | -42.9% | 429 | 0.0% | 0.00% | – |
| Q4 2021 | $7,000 | -70.8% | 429 | -16.4% | 0.00% | – |
| Q3 2021 | $24,000 | +33.3% | 513 | +73.9% | 0.00% | – |
| Q2 2021 | $18,000 | 0.0% | 295 | 0.0% | 0.00% | – |
| Q1 2021 | $18,000 | +12.5% | 295 | +27.7% | 0.00% | – |
| Q4 2020 | $16,000 | -38.5% | 231 | -66.9% | 0.00% | – |
| Q3 2020 | $26,000 | +30.0% | 697 | 0.0% | 0.00% | – |
| Q2 2020 | $20,000 | 0.0% | 697 | 0.0% | 0.00% | – |
| Q1 2020 | $20,000 | -16.7% | 697 | 0.0% | 0.00% | – |
| Q4 2019 | $24,000 | – | 697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |